28 May 2015

Company Announcements Office
Australian Securities Exchange

Appendix 3Y
Change of Director’s Interest Notice

Attached is an Appendix 3Y- Change of Director’s Interest Notice in respect of changes in the relevant interests in securities held by Mr Maurie Stang, Non-Executive Chairman of Nanosonics.

Mr Stang has completed an on-market sale of 3,302,723 ordinary shares in Nanosonics Limited which was made in compliance with the Company’s Secuities Trading Policy. Following the sale, Mr Stang is Nanosonics’ largest shareholder with 25,099,701 ordinary shares representing 8.9% of the Company’s issued share capital.

McGregor Grant
Secretary

For more information please contact:
Michael Kavanagh, CEO / President or McGregor Grant, CFO, on (02) 8063 1600
Kyahn Williamson, Investor Relations, Buchan Consulting on (03) 9866 4722
Ben Walsh, Media Relations, Buchan Consulting on (03) 9866 4722.

About Nanosonics
Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets. Initial market applications are designed for the reprocessing of reusable medical instruments. The Company’s first product is designed to disinfect Ultrasound Transducers. For more information about Nanosonics please visit www.nanosonics.com.au

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**Nanosonics Limited**
ABN	**11 095 076 896**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Maurie Stang
Date of last notice	16 July 2013

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	a) Direct b) Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect shares held in names of Novapharm Research (Australia) Pty Ltd and Epitek Corporation Pty Ltd
Date of change	26 May 2015
No. of securities held prior to change	a) Direct: 28,286,056 ordinary shares, fully paid. b) Indirect: 116,368 ordinary shares, fully paid.
Class	Ordinary shares, fully paid.
Number acquired	Nil
Number disposed	3,302,723
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$6,043,983.09

+ See chapter 19 for defined terms.

No. of securities held after change	c) Direct: 24,983,333 ordinary shares, fully paid. d) Indirect: 116,368 ordinary shares, fully paid.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market sale of ordinary shares.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder **(if issued securities**	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Director: Maurie Stang
Date 28 May 2015

+ See chapter 19 for defined terms.